Pier Luigi Zinzani

Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton’s tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).

Chat with BeiGene

Close